Navigation Links
No Scientific Evidence to Support Drug Safety Recommendations

During the past several years, there has been a perceived drug safety crisis in the United States.//

A recent editorial published in Health Economics finds no scientific evidence to back up the IOM’s recommendations released recently and little evidence of a drug safety crisis.

The current drug controversy is largely due to the withdrawal of Vioxx from the market, but the decrease in drug approval times thanks to the Prescription Drug User Fee Acts (PDUFA), and undue influence from the pharmaceutical industry that these acts may have invited have also played a role. Yet the scientific basis that too many unsafe drugs enter the market is lacking.

The IOM report does not document, for example, whether the reductions in approval times for bringing drugs to the market negatively affects the well-being of consumers.

The editorial points to a study that the social benefit from reducing drug approval times from 1979 to 2002 —a sum estimated at $16 to $32 billion dollars—substantially outweighed any decrease in safety.

Although a lengthier approval process might reduce the number of drug withdrawals, this doesn’t necessarily mean that too many drugs are withdrawn.

Removing a few drugs from the market may be a necessary price to pay for bringing a larger number of medications more quickly to the public.

The report recommends a two-year ban on advertising drugs directly to consumers because it may lead to increased exposure to unsafe drugs, but it would also mean that fewer consumers would benefit from these medications.

Also, it is not clear if restricting this advertising would limit consumption since it represents only a 15% share of total advertising expenditures.

The authors agree with the report’s recommendation that extensive testing should be done after drugs are on the market. “The science of approval is far more elaborate than the science of withdrawal, many times done under gr eat political pressure,” they note.

They point to a strong need for FDA-mandated post-approval studies, since pharmaceutical companies have little incentive to undertake this research on their own, as it could potentially lower their profits.

The FDA has picked up on this point; at the end of January, the agency announced a new policy to comprehensively assess drugs 18 months after they are introduced.

Source-EurekalertPRI
'"/>




Related medicine news :

1. Scientific markers of aging described
2. A Settlement Over Stem Cell Controversy Through Scientific Research
3. A Scientific Explanation For Out Of Body Experience
4. PUFA Good For Heart: Gets The Scientific Seal
5. Forensic Phonetics – Scientific Solution for Legal Problem
6. Old Indian Advice Has A Scientific Backing Now!
7. India To Highlight Its Scientific Achievements
8. Scientific Research in a War Zone
9. Evidence Links Protein Damage to Neurodegenerative diseases like Parkinsons and Alzheimers
10. Evidence supporting H.pylori eradication
11. Evidence against use of Beta blockers as first choice in the treatment of primary hypertension
Post Your Comments:
*Name:
*Comment:
*Email:


(Date:3/27/2017)... ... March 27, 2017 , ... The Anaheim Hills office ... First National Capital has added 10 new sales professionals over the past 6 months ... by 15 additional new hires over the course of 2017. , “This new ...
(Date:3/27/2017)... Orange, Texas (PRWEB) , ... March 27, 2017 ... ... celebration at the GTEC Orange facility from 8:00am-10:00am on Monday, April 3rd to ... giveaways and will be an opportunity for area-residents to celebrate two great years ...
(Date:3/26/2017)... ... March 26, 2017 , ... Local physician Dr. Justin ... a prestigious award honoring the top influencers on RealSelf—the most trusted online destination ... doctors and clinics. , In 2016, more than 82 million people visited RealSelf ...
(Date:3/24/2017)... ... March 24, 2017 , ... Vighter ... the same time by providing Prehospital Trauma Life Support (PHTLS) course scholarships to ... premier prehospital trauma education developed in cooperation with the American College of Surgeons ...
(Date:3/24/2017)... ... ... The Radiology Business Management Association (RBMA) has named the nine winners ... year, are among the most prestigious in radiology marketing because a panel of radiology ... recognize achievements in both large budget (over $5,000) and small budget (under $5,000) campaigns. ...
Breaking Medicine News(10 mins):
(Date:3/27/2017)... BOSTON , March 27, 2017 ... pharmaceutical company and Paratek Pharmaceuticals, Inc. (Nasdaq: PRTK), ... commercialization of innovative therapies based upon tetracycline chemistry, ... sarecycline for the treatment of moderate to severe ... Sarecycline is a once-daily, oral, narrow spectrum tetracycline-derived ...
(Date:3/27/2017)... 2017  Impax Laboratories, Inc. (NASDAQ: IPXL)today announced that ... Bisaro as Impax,s President and Chief Executive Officer ... 27, 2017. Mr. Bisaro will succeed J. Kevin ... Chief Executive Officer since December of 2016. ... experience, Mr. Bisaro, 56, is an accomplished global business ...
(Date:3/27/2017)... 27, 2017  PhaseRx, Inc. (NASDAQ: PZRX), a ... liver diseases in children, today reported financial results ... December 31, 2016 and provided an update on ... to make progress during the fourth quarter of ... our non-human primate safety study, and with our lead ...
Breaking Medicine Technology: